7-8-04

+

UIL Delease type and us sign (+) inside this box →

W 1632

PTO/SB/21 (05-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


					Application Number	10/017,71	8		
TDANOLUTTAL					Filing Date	Decembe	December 14, 2001		
	TRA	NSMITTAL	-		First Named Inventor	WEISGR	ABER, KARL H.		
		FORM			Group Art Unit	1632			
	(to be used for all	correspondence after ini	tial filing)		Examiner Name	TON, TH	AIAN N.		
	f Pages in This Submissi	ion		Attorney Docket Number	UCAL-22	2			
	Total Number o	Trages III Triis Submissi		SUR	ES (check all that apply)				
	Extension of To	ched Reply al s/declaration(s) time Request donment Request sclosure Statement of Priority fissing Parts/		Assign (for an Drawin Licens Petitio Petitio Provis Power Chang Addres Termin	nment Papers o Application) ng(s) sing-related Papers on to Convert to a cional Application of Attorney, Revocation ge of Correspondence	1) 2) 3) 4) 5)	After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below): Exhibit 1-3 Sequence Listing Certification and Amendment (3 pgs.) Sequence Listing (9 pgs.) Sequence Listing (1 CD – CRF Format) Return Postcard		
		SIGNA	TURE OF	APPL	ICANT, ATTORNEY, O	RAGENT			
Signing Attorney/Agent (Reg. No.)		PAULA A. BORDEN, 42,334 BOZICEVIC, FIELD & FRANCIS LLP							
Signature		Jana 1							
Date		July 6, 2004							

EXPRESS MAIL LABEL NO. EV333997180US

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.





Express Mail No. EV333997180US

AMENDMENT UNDER	Attorney Docket	UCAL222 5282 K.H. Weisgraber 10/017,718 December 14, 2001 1632 T.N. Ton	
37 C.F.R. §1.111	Confirmation No.		
57 C.I.III gIIII	First Named Inventor		
	Application Number		
Address to:	Filing Date		
Commissioner for Patents	Group Art Unit		
	Examiner Name		
P.O. Box 1450 Alexandria, VA 22313-1450	Title	Gene-targeted animal model of apolipoprotein E4 domain interaction and uses thereof	

Sir:

This amendment is responsive to the Office Action dated April 20, 2004, for which a three-month period for response was given, making this response due on or before July 20, 2004. Accordingly, this response is timely filed.

In view of the remarks put forth below, reconsideration and allowance are respectfully requested.